Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. ARWR
stocks logo

ARWR

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q1
FY2026Q2
FY2026Q3
200.76M
+7930.39%
-0.595
-57.19%
66.28M
-87.79%
-0.837
-130.42%
--
--
-1.322
+4.89%
Estimates Revision
The market is revising Upward the revenue expectations for Arrowhead Pharmaceuticals, Inc. (ARWR) for FY2026, with the revenue forecasts being adjusted by 8.02% over the past three months. During the same period, the stock price has changed by 122.39%.
Revenue Estimates for FY2026
Revise Upward
up Image
+8.02%
In Past 3 Month
EPS Estimates for FY2026
Revise Upward
up Image
+4.5%
In Past 3 Month
Stock Price
Go Up
up Image
+122.39%
In Past 3 Month
Wall Street analysts forecast ARWR stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ARWR is 49.00 USD with a low forecast of 17.00 USD and a high forecast of 80.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
Wall Street analysts forecast ARWR stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ARWR is 49.00 USD with a low forecast of 17.00 USD and a high forecast of 80.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
4 Hold
0 Sell
Moderate Buy
Current: 64.660
sliders
Low
17.00
Averages
49.00
High
80.00
Current: 64.660
sliders
Low
17.00
Averages
49.00
High
80.00
H.C. Wainwright
H.C. Wainwright
Buy
maintain
$80 -> $85
2025-12-02
New
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$80 -> $85
2025-12-02
New
maintain
Buy
Reason
H.C. Wainwright raised the firm's price target on Arrowhead to $85 from $80 and keeps a Buy rating on the shares. The firm says the company's "transformative" fiscal Q4 was driven by FDA approval of Redemplo for familial chylomicronemia syndrome. This marks an "inflection point" for Arrowhead's RNA interference pipeline, the analyst tells investors in a research note. H.C. Wainwright cites increased conviction that Arrowhead is entering a sustained period of clinical, regulatory, and commercial value creation for the target bump.
Morgan Stanley
Equal Weight
maintain
$45 -> $48
2025-11-26
Reason
Morgan Stanley
Price Target
$45 -> $48
2025-11-26
maintain
Equal Weight
Reason
Morgan Stanley raised the firm's price target on Arrowhead to $48 from $45 and keeps an Equal Weight rating on the shares. Redemplo's approval in FCS last week "importantly sets the stage for meaningful label expansion into SHTG," the analyst tells investors. Phase 3 SHASTA 3 & 4 studies of plozasiran in SHTG are on track for Q3 of 2026 and management pointed to "a decent chance for success on pancreatitis," the analyst added.
Goldman Sachs
Neutral
maintain
$27 -> $48
2025-11-19
Reason
Goldman Sachs
Price Target
$27 -> $48
2025-11-19
maintain
Neutral
Reason
Goldman Sachs raised the firm's price target on Arrowhead to $48 from $27 but keeps a Neutral rating on the shares. The firm is citing the announced FDA approval of Redemplo, formerly plozasiran, as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome, in what it calls a "best case" label scenario, the analyst tells investors in a research note. Goldman adds however that Redemplo's pricing could serve Arrowhead favorably in the near-term during the FCS launch, as both Ionis (IONS) and Arrowhead transition to the sHTG launch, the dynamic may become more nuanced.
Piper Sandler
Edward Tenthoff
Overweight
upgrade
$45 -> $70
2025-11-19
Reason
Piper Sandler
Edward Tenthoff
Price Target
$45 -> $70
2025-11-19
upgrade
Overweight
Reason
Piper Sandler analyst Edward Tenthoff raised the firm's price target on Arrowhead to $70 from $45 and keeps an Overweight rating on the shares. The firm notes the FDA approved Arrowhead's first-ever TRiM medicine Redemplo as an adjunct to diet to reduce triglycerides in adults with Familial Chylomicronemia Syndrome. While Tryngolza has a head start and is off to a solid launch, Piper believes that Redemplo will compete well in FCS based on deeper placebo-adjusted TG reductions, less frequent quarterly injections and lower WAC of $60,000 vs. $595,000. The firm forecasts U.S. Redemplo FCS sales of at least $625,000 in Q4 2025, $12.3M in 2026 growing to $172M by 2031. Further, Piper is confident Arrowhead will report positive Phase III SHASTA-3, SHASTA-4 and MUIR-3 trials on Redemplo in severe hypertriglyceridemia in Q3 2026, with the potential for blockbuster label expansion in 2027.
Morgan Stanley
analyst
Equal Weight
maintain
$29 -> $45
2025-11-12
Reason
Morgan Stanley
analyst
Price Target
$29 -> $45
2025-11-12
maintain
Equal Weight
Reason
Morgan Stanley raised the firm's price target on Arrowhead (ARWR) to $45 from $29 and keeps an Equal Weight rating on the shares. Recent data from Ionis' (IONS) Phase 3 CORE/CORE2 studies of olezarsen in severe hypertriglyceridemia increases the firm's conviction in the potential of Arrowhead's plozasiran in SHTG, notes the analyst, who updated the firm's model ahead of key SHASTA 3/4 data expected in Q3 of 2026.
B. Riley
Buy
maintain
$38 -> $61
2025-10-22
Reason
B. Riley
Price Target
$38 -> $61
2025-10-22
maintain
Buy
Reason
B. Riley raised the firm's price target on Arrowhead to $61 from $38 and keeps a Buy rating on the shares. The firm says "structural" cost advantages position Arrowhead to capture "disproportionate value" in high prevalence cardiovascular-met and rare neuromuscular indications. B. Riley's analysis indicates Arrowhead's constructs could achieve annual per-patient costs of goods sold advantages of five-times peer bioconjugate platforms, which it feels is an "underappreciated differential material to long-term gross margin assumptions."
See All Ratings

Valuation Metrics

The current forward P/E ratio for Arrowhead Pharmaceuticals Inc (ARWR.O) is -20.44, compared to its 5-year average forward P/E of -26.84. For a more detailed relative valuation and DCF analysis to assess Arrowhead Pharmaceuticals Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-26.84
Current PE
-20.44
Overvalued PE
6.50
Undervalued PE
-60.18

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-29.86
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
5.41
Undervalued EV/EBITDA
-65.14

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
24.46
Current PS
0.00
Overvalued PS
38.30
Undervalued PS
10.61
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

ARWR News & Events

Events Timeline

(ET)
2025-12-03
12:10:00
Arrowhead Stock Rises 9.7% to $63.59
select
2025-12-02 (ET)
2025-12-02
07:50:00
Arrowhead Receives FDA Breakthrough Therapy Designation for Plozasiran
select
2025-12-01 (ET)
2025-12-01
07:50:00
BofA Raises Arrowhead Price Target to $62 from $42, Maintains Buy Rating
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
12-02Newsfilter
Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran in Severe Hypertriglyceridemia
  • FDA Designation: Arrowhead's plozasiran has received Breakthrough Therapy designation from the FDA, aimed at aiding millions globally suffering from severe hypertriglyceridemia, indicating its potential to outperform existing therapies on clinically significant endpoints.
  • Clinical Trial Progress: Arrowhead is on track to complete the SHASTA-3, SHASTA-4, and MUIR-3 Phase 3 clinical studies by mid-2026, with plans to submit a supplemental New Drug Application to the FDA by the end of 2026, thereby accelerating the product's market entry.
  • Market Demand: With limited treatment options available for severe hypertriglyceridemia patients, plozasiran, as the first RNA interference therapy targeting apoC-III, may provide new hope and meet the urgent market demand for effective treatments.
  • Global Expansion Plans: Following FDA approval, Arrowhead intends to seek regulatory approval from additional global authorities, demonstrating its ambition to expand in international markets and enhance its competitiveness in the biopharmaceutical sector.
[object Object]
Preview
9.0
12-02SeekingAlpha
Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran

  • FDA Breakthrough Therapy Designation: Arrowhead Pharmaceuticals' investigational drug, plozasiran, has received Breakthrough Therapy designation from the FDA to help lower triglyceride levels in adults with severe hypertriglyceridemia.

  • Clinical Trials Timeline: The company is on track to complete its phase 3 clinical trials for plozasiran, known as SHASTA-3, SHASTA-4, and MUIR-3, by mid-2026.

[object Object]
Preview
6.0
12-02Benzinga
B of A Securities Reaffirms Buy Rating on Arrowhead Pharma, Increases Price Target to $62

  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts to help traders stay informed and make timely decisions in the stock market.

  • Exclusive Content: Subscribers gain access to unique stories and insights generated by Benzinga reporters, enhancing their trading strategies.

  • Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, sharing knowledge and experiences.

  • Market Winning Tools: The platform is designed to provide traders with the tools and information necessary to succeed in their trading endeavors.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Arrowhead Pharmaceuticals Inc (ARWR) stock price today?

The current price of ARWR is 64.66 USD — it has decreased -0.64 % in the last trading day.

arrow icon

What is Arrowhead Pharmaceuticals Inc (ARWR)'s business?

Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. The Company's Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. It is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, muscle and central nervous system. It has around 16 clinical-stage investigational medicines (wholly owned and partnered), which range in development stage from Phase I to Phase III. The Company's pipeline products include Plozasiran, Zodasiran, Olpasiran, ARO-RAGE, ARO-MMP7, GSK-4532990, Fazirsiran, GSK5637608, ARO-CFB, ARO-INHBE, ARO-C3, ARO-PNPLA3, ARO-DUX4, ARO-DM1 and ARO-ATXN2.

arrow icon

What is the price predicton of ARWR Stock?

Wall Street analysts forecast ARWR stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ARWR is 49.00 USD with a low forecast of 17.00 USD and a high forecast of 80.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Arrowhead Pharmaceuticals Inc (ARWR)'s revenue for the last quarter?

Arrowhead Pharmaceuticals Inc revenue for the last quarter amounts to 256.47M USD, decreased % YoY.

arrow icon

What is Arrowhead Pharmaceuticals Inc (ARWR)'s earnings per share (EPS) for the last quarter?

Arrowhead Pharmaceuticals Inc. EPS for the last quarter amounts to -0.17 USD, decreased -87.59 % YoY.

arrow icon

What changes have occurred in the market's expectations for Arrowhead Pharmaceuticals Inc (ARWR)'s fundamentals?

The market is revising Upward the revenue expectations for Arrowhead Pharmaceuticals, Inc. (ARWR) for FY2026, with the revenue forecasts being adjusted by 8.02% over the past three months. During the same period, the stock price has changed by 122.39%.
arrow icon

How many employees does Arrowhead Pharmaceuticals Inc (ARWR). have?

Arrowhead Pharmaceuticals Inc (ARWR) has 711 emplpoyees as of December 05 2025.

arrow icon

What is Arrowhead Pharmaceuticals Inc (ARWR) market cap?

Today ARWR has the market capitalization of 8.78B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free